Trade 2seventy bio, Inc. - TSVT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 2.63 |
Open* | 2.66 |
1-Year Change* | -81.49% |
Day's Range* | 2.66 - 3.06 |
52 wk Range | 1.55-16.17 |
Average Volume (10 days) | 1.93M |
Average Volume (3 months) | 37.79M |
Market Cap | 79.48M |
P/E Ratio | -100.00K |
Shares Outstanding | 50.62M |
Revenue | 145.88M |
EPS | -3.91 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Mar 11, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 8, 2023 | 3.06 | 0.44 | 16.79% | 2.62 | 3.08 | 2.56 |
Dec 7, 2023 | 2.63 | 0.31 | 13.36% | 2.32 | 2.67 | 2.26 |
Dec 6, 2023 | 2.32 | 0.23 | 11.00% | 2.09 | 2.44 | 2.09 |
Dec 5, 2023 | 2.13 | 0.10 | 4.93% | 2.03 | 2.18 | 2.00 |
Dec 4, 2023 | 2.04 | 0.16 | 8.51% | 1.88 | 2.18 | 1.86 |
Dec 1, 2023 | 1.92 | 0.12 | 6.67% | 1.80 | 1.92 | 1.65 |
Nov 30, 2023 | 1.81 | -0.08 | -4.23% | 1.89 | 1.95 | 1.80 |
Nov 29, 2023 | 1.89 | 0.04 | 2.16% | 1.85 | 2.06 | 1.85 |
Nov 28, 2023 | 1.84 | 0.01 | 0.55% | 1.83 | 1.89 | 1.72 |
Nov 27, 2023 | 1.79 | 0.04 | 2.29% | 1.75 | 1.87 | 1.70 |
Nov 24, 2023 | 1.71 | 0.04 | 2.40% | 1.67 | 1.87 | 1.64 |
Nov 22, 2023 | 1.71 | 0.13 | 8.23% | 1.58 | 1.71 | 1.51 |
Nov 21, 2023 | 1.54 | -0.17 | -9.94% | 1.71 | 1.72 | 1.53 |
Nov 20, 2023 | 1.71 | 0.03 | 1.79% | 1.68 | 1.84 | 1.63 |
Nov 17, 2023 | 2.10 | -0.08 | -3.67% | 2.18 | 2.27 | 2.02 |
Nov 16, 2023 | 2.09 | -0.21 | -9.13% | 2.30 | 2.30 | 2.05 |
Nov 15, 2023 | 2.29 | 0.08 | 3.62% | 2.21 | 2.48 | 2.21 |
Nov 14, 2023 | 2.24 | 0.13 | 6.16% | 2.11 | 2.61 | 1.86 |
Nov 13, 2023 | 2.23 | 0.13 | 6.19% | 2.10 | 2.24 | 1.99 |
Nov 10, 2023 | 2.14 | -0.14 | -6.14% | 2.28 | 2.28 | 2.14 |
2seventy bio, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, March 11, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 2Seventy Bio Inc Earnings Release Q4 2023 2Seventy Bio Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 91.496 | 54.522 | 248.122 | 44.296 | 54.579 |
Revenue | 91.496 | 54.522 | 248.122 | 44.296 | 54.579 |
Cost of Revenue, Total | 16.577 | 2.517 | 5.396 | 2.978 | 0.885 |
Gross Profit | 74.919 | 52.005 | 242.726 | 41.318 | 53.694 |
Total Operating Expense | 354.636 | 368.47 | 386.292 | 385.016 | 258.005 |
Selling/General/Admin. Expenses, Total | 79.45 | 93.506 | 90.897 | 81.646 | 53.631 |
Research & Development | 248.735 | 261.937 | 296.467 | 297.645 | 200.49 |
Other Operating Expenses, Total | 0.232 | 0.439 | -6.468 | 2.747 | 2.999 |
Operating Income | -263.14 | -313.948 | -138.17 | -340.72 | -203.426 |
Interest Income (Expense), Net Non-Operating | 2.932 | 0.088 | 0 | 0 | -15.486 |
Other, Net | 6.055 | 21.647 | 18.056 | 20.126 | 19.163 |
Net Income Before Taxes | -254.153 | -292.213 | -120.114 | -320.594 | -199.749 |
Net Income After Taxes | -254.153 | -292.213 | -120.114 | -320.594 | -199.749 |
Net Income Before Extra. Items | -254.153 | -292.213 | -120.114 | -320.594 | -199.749 |
Net Income | -254.153 | -292.213 | -120.114 | -320.594 | -199.749 |
Income Available to Common Excl. Extra. Items | -254.153 | -292.213 | -120.114 | -320.594 | -199.749 |
Income Available to Common Incl. Extra. Items | -254.153 | -292.213 | -120.114 | -320.594 | -199.749 |
Diluted Net Income | -254.153 | -292.213 | -120.114 | -320.594 | -199.749 |
Diluted Weighted Average Shares | 35.637 | 23.499 | 23.3691 | 23.3691 | 23.3691 |
Diluted EPS Excluding Extraordinary Items | -7.13172 | -12.4351 | -5.13987 | -13.7187 | -8.54757 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Diluted Normalized EPS | -6.86116 | -12.0065 | -5.13987 | -13.7187 | -8.54757 |
Unusual Expense (Income) | 9.642 | 10.071 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 36.048 | 41.621 | 56.177 | 13.408 | 13.482 |
Revenue | 36.048 | 41.621 | 56.177 | 13.408 | 13.482 |
Cost of Revenue, Total | 4.517 | 4.295 | 15.325 | 0.377 | 4.246 |
Gross Profit | 31.531 | 37.326 | 40.852 | 13.031 | 9.236 |
Total Operating Expense | 84.039 | 93.334 | 83.389 | 81.776 | 90.454 |
Selling/General/Admin. Expenses, Total | 19.489 | 20.72 | 18.701 | 19.61 | 17.278 |
Research & Development | 59.98 | 68.246 | 49.312 | 61.739 | 64.557 |
Other Operating Expenses, Total | 0.053 | 0.073 | 0.051 | 0.05 | 0.083 |
Operating Income | -47.991 | -51.713 | -27.212 | -68.368 | -76.972 |
Interest Income (Expense), Net Non-Operating | 3.09 | 2.049 | 1.491 | 1.113 | 0.213 |
Other, Net | 2.812 | 2.643 | 2.561 | -0.624 | -0.661 |
Net Income Before Taxes | -42.089 | -47.021 | -23.16 | -67.879 | -77.42 |
Net Income After Taxes | -42.089 | -47.021 | -23.143 | -67.879 | -77.42 |
Net Income Before Extra. Items | -42.089 | -47.021 | -23.143 | -67.879 | -77.42 |
Net Income | -42.089 | -47.021 | -23.143 | -67.879 | -77.42 |
Income Available to Common Excl. Extra. Items | -42.089 | -47.021 | -23.143 | -67.879 | -77.42 |
Income Available to Common Incl. Extra. Items | -42.089 | -47.021 | -23.143 | -67.879 | -77.42 |
Diluted Net Income | -42.089 | -47.021 | -23.143 | -67.879 | -77.42 |
Diluted Weighted Average Shares | 50.966 | 43.468 | 38.712 | 38.573 | 38.381 |
Diluted EPS Excluding Extraordinary Items | -0.82583 | -1.08174 | -0.59782 | -1.75975 | -2.01714 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.82583 | -1.08174 | -0.59782 | -1.75975 | -1.90537 |
Unusual Expense (Income) | 0 | 0 | 0 | 0 | 4.29 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 300.882 | 291.564 | 25.104 | 20.842 | |
Total Receivables, Net | 20.96 | 16.995 | 10.691 | 7.426 | |
Accounts Receivable - Trade, Net | 20.96 | 16.995 | 10.691 | 7.426 | |
Prepaid Expenses | 13.652 | 9.512 | 14.413 | 13.416 | |
Total Assets | 656.665 | 759.675 | 312.62 | 314.949 | |
Property/Plant/Equipment, Total - Net | 296.62 | 310.447 | 260.481 | 257.521 | |
Property/Plant/Equipment, Total - Gross | 344.458 | 350.525 | 290.518 | 278.237 | |
Accumulated Depreciation, Total | -47.838 | -40.078 | -30.037 | -20.716 | |
Goodwill, Net | 12.056 | 12.056 | 13.128 | 13.128 | |
Intangibles, Net | 7.302 | 9.892 | 5.644 | 9.406 | |
Other Long Term Assets, Total | 38.391 | 38.592 | 8.263 | 14.052 | |
Total Current Liabilities | 79.794 | 98.388 | 75.868 | 103.397 | |
Accounts Payable | 7.208 | 6.024 | 7.152 | 20.389 | |
Accrued Expenses | 65.842 | 65.179 | 58.66 | 64.154 | |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
Other Current Liabilities, Total | 6.744 | 27.185 | 10.056 | 18.854 | |
Total Liabilities | 346.199 | 399.853 | 237.991 | 271.257 | |
Total Long Term Debt | 0 | 0 | 0 | 0 | |
Other Liabilities, Total | 266.405 | 301.465 | 162.123 | 167.86 | |
Total Equity | 310.466 | 359.822 | 74.629 | 43.692 | |
Other Equity, Total | -2.877 | -0.712 | 74.629 | 43.692 | |
Total Liabilities & Shareholders’ Equity | 656.665 | 759.675 | 312.62 | 314.949 | |
Total Common Shares Outstanding | 37.928 | 23.585 | 23.3691 | 23.3691 | |
Cash and Short Term Investments | 266.27 | 265.057 | |||
Cash & Equivalents | 71.032 | 130.414 | |||
Short Term Investments | 195.238 | 134.643 | |||
Long Term Investments | 1.414 | 97.124 | |||
Common Stock | 0.004 | 0.002 | |||
Additional Paid-In Capital | 606.986 | 400.026 | |||
Retained Earnings (Accumulated Deficit) | -293.647 | -39.494 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 277.254 | 333.665 | 389.817 | 300.882 | 349.417 |
Total Receivables, Net | 19.515 | 44.099 | 41.252 | 20.96 | 12.037 |
Accounts Receivable - Trade, Net | 19.515 | 44.099 | 41.252 | 20.96 | 12.037 |
Prepaid Expenses | 7.12 | 6.729 | 8.635 | 13.652 | 14.27 |
Total Assets | 640.806 | 705.713 | 742.437 | 656.665 | 708.744 |
Property/Plant/Equipment, Total - Net | 285.234 | 291.735 | 294.417 | 296.62 | 300.108 |
Property/Plant/Equipment, Total - Gross | 339.292 | 343.712 | 344.332 | 344.458 | 345.798 |
Accumulated Depreciation, Total | -54.058 | -51.977 | -49.915 | -47.838 | -45.69 |
Goodwill, Net | 0 | 12.056 | 12.056 | 12.056 | 12.056 |
Intangibles, Net | 6.771 | 6.948 | 7.125 | 7.302 | 7.479 |
Other Long Term Assets, Total | 37.888 | 37.6 | 37.59 | 38.391 | 38.277 |
Total Current Liabilities | 68.008 | 66.895 | 76.929 | 79.794 | 79.897 |
Accounts Payable | 5.307 | 6.274 | 13.399 | 7.208 | 7.983 |
Accrued Expenses | 49.675 | 47.979 | 55.05 | 65.842 | 62.954 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 13.026 | 12.642 | 8.48 | 6.744 | 8.96 |
Total Liabilities | 334.384 | 338.218 | 341.113 | 346.199 | 385.564 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 266.376 | 271.323 | 264.184 | 266.405 | 305.667 |
Total Equity | 306.422 | 367.495 | 401.324 | 310.466 | 323.18 |
Other Equity, Total | -0.916 | -1.43 | -1.95 | -2.877 | -3.886 |
Total Liabilities & Shareholders’ Equity | 640.806 | 705.713 | 742.437 | 656.665 | 708.744 |
Total Common Shares Outstanding | 50.616 | 50.238 | 50.19 | 37.928 | 37.912 |
Cash and Short Term Investments | 250.619 | 282.837 | 339.93 | 266.27 | 323.11 |
Cash & Equivalents | 90.226 | 95.991 | 193.629 | 71.032 | 127.021 |
Short Term Investments | 160.393 | 186.846 | 146.301 | 195.238 | 196.089 |
Long Term Investments | 33.659 | 23.709 | 1.432 | 1.414 | 1.407 |
Common Stock | 0.005 | 0.005 | 0.005 | 0.004 | 0.004 |
Additional Paid-In Capital | 761.728 | 751.677 | 743.937 | 606.986 | 597.566 |
Retained Earnings (Accumulated Deficit) | -454.395 | -382.757 | -340.668 | -293.647 | -270.504 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -254.153 | -292.213 | -120.114 | -320.594 | -199.749 |
Cash From Operating Activities | -237.134 | -207.034 | -67.793 | -207.957 | -146.215 |
Cash From Operating Activities | 11.533 | 16.35 | 13.188 | 12.587 | 13.345 |
Non-Cash Items | 41.357 | 55.498 | 54.602 | 64.906 | 44.007 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0 | 0 | 0 | 0 | 15.486 |
Changes in Working Capital | -35.871 | 13.331 | -15.469 | 35.144 | -3.818 |
Cash From Investing Activities | 11.697 | 15.411 | -22.261 | -59.765 | -50.827 |
Capital Expenditures | -22.842 | -19.575 | -22.261 | -59.765 | -50.827 |
Cash From Financing Activities | 166.229 | 354.889 | 90.054 | 267.722 | 197.042 |
Financing Cash Flow Items | 0 | 0 | 3.098 | ||
Issuance (Retirement) of Stock, Net | 166.229 | 354.889 | 90.054 | 267.722 | 194.961 |
Issuance (Retirement) of Debt, Net | 0 | 0 | -1.017 | ||
Net Change in Cash | -59.208 | 163.266 | 0 | 0 | 0 |
Other Investing Cash Flow Items, Total | 34.539 | 34.986 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -47.021 | -254.153 | -231.01 | -163.131 | -85.711 |
Cash From Operating Activities | -49.088 | -237.134 | -181.654 | -120.725 | -73.482 |
Cash From Operating Activities | 2.255 | 11.533 | 9.208 | 6.831 | 3.53 |
Non-Cash Items | 8.535 | 41.357 | 32.89 | 20.866 | 11.014 |
Cash Taxes Paid | 0 | ||||
Cash Interest Paid | 0 | ||||
Changes in Working Capital | -12.857 | -35.871 | 7.258 | 14.709 | -2.315 |
Cash From Investing Activities | 44.798 | 11.697 | 12.229 | 94.519 | 44.749 |
Capital Expenditures | -6.079 | -22.842 | -19.676 | -6.258 | -3.585 |
Cash From Financing Activities | 127.084 | 166.229 | 165.997 | 165.822 | 170.099 |
Financing Cash Flow Items | |||||
Issuance (Retirement) of Stock, Net | 127.084 | 166.229 | 165.997 | 165.822 | 170.099 |
Issuance (Retirement) of Debt, Net | |||||
Net Change in Cash | 122.794 | -59.208 | -3.428 | 139.616 | 141.366 |
Other Investing Cash Flow Items, Total | 50.877 | 34.539 | 31.905 | 100.777 | 48.334 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Kynam Capital Management LP | Hedge Fund | 11.798 | 5953825 | 1063119 | 2023-08-31 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.187 | 3626865 | 842492 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.8785 | 3471194 | 573640 | 2023-06-30 | LOW |
Millennium Management LLC | Hedge Fund | 5.7376 | 2895476 | 383825 | 2023-06-30 | HIGH |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 5.7068 | 2879922 | 110480 | 2023-06-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 4.9491 | 2497526 | 0 | 2023-06-30 | LOW |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 4.7392 | 2391628 | 0 | 2023-06-30 | LOW |
Casdin Capital, LLC | Hedge Fund | 4.0106 | 2023913 | 0 | 2023-06-30 | LOW |
ExodusPoint Capital Management, LP | Hedge Fund | 2.8879 | 1457390 | 428350 | 2023-06-30 | HIGH |
Bain Capital Life Sciences Investors, LLC | Investment Advisor | 2.7919 | 1408901 | 0 | 2023-06-30 | LOW |
Avidity Partners Management LP | Hedge Fund | 2.6593 | 1342000 | 1342000 | 2023-06-30 | HIGH |
Goldman Sachs & Company, Inc. | Research Firm | 2.5416 | 1282617 | -154546 | 2023-06-30 | MED |
Point72 Asset Management, L.P. | Hedge Fund | 2.5304 | 1276952 | 1065673 | 2023-06-30 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.1186 | 1069125 | -1991081 | 2023-09-30 | LOW |
Credit Suisse Funds AG | Investment Advisor/Hedge Fund | 2.0023 | 1010450 | -7315 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9483 | 983226 | 241754 | 2023-06-30 | LOW |
Cowen Investment Management LLC | Investment Advisor/Hedge Fund | 1.6883 | 852007 | -2993 | 2023-06-30 | HIGH |
JP Morgan Asset Management | Investment Advisor | 1.4683 | 740947 | -367190 | 2023-06-30 | LOW |
Newtyn Management, LLC | Hedge Fund | 1.4619 | 737744 | -767256 | 2023-06-30 | MED |
Morgan Stanley & Co. LLC | Research Firm | 1.3142 | 663190 | -216995 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
2seventy bio, Inc. Company profile
About 2Seventy Bio Inc
2Seventy Bio, Inc. is a cell and gene therapy company. The Company is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. It is advancing multiple preclinical and clinical programs in oncology. The Company's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. It is developing bbT369 product candidate as a treatment for patients with B-NHL.
Financial summary
BRIEF: For the nine months ended 30 September 2021, 2Seventy Bio Inc revenues totaled $38.5M. Net loss totaled to $231.2M.
Industry: | Biotechnology & Medical Research (NEC) |
60 Binney Street
CAMBRIDGE
MASSACHUSETTS 02210
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com